The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 9.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are up 31%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (11 analysts) rates it buy, with a mean price target of $4950.
British American Tobacco
BATS.L · LSE · GBp · Market cap $92.3B
FAIL · Does not pass the screenPrice as of 13 Nov 2026Daily close, not a live quote
Screened 2026-11-13 · the tape above runs as of 10:20 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price4,656.00 GBp at the 13 Nov 2026 close
- Fair value2,328.00. Our model only; no analyst estimate to cross-check.
- Our value readOvervalued vs our fair value, as of 13 Nov 2026
- Our regime readMarkup, as of 15 Nov 2026
- Ethical screenDoes not pass
- Last reviewed13 Nov 2026 (3 days ago)
- Release timesRelease and earnings times on your chart: Event Guard Mentor
A summary of the dated readings below, not a live quote and not advice.
Our fair-value range: range not available, base estimate 2,328.00 GBp (screen dated 2026-11-13).
- Trend Markup
- Insiders no filings inside 60 days, left as found
- Positioning no disclosures inside 60 days, left as found
- Options no verdict drawn today, left as found
- Ethical does not pass the values gate
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
This name holds its markup label.
British American Tobacco holds its Markup at $4,656.00. Consolidating, no directional conviction, held for 25 days.
| Phase | Markup |
| Quantitative state | Consolidating, no directional conviction, held for 25 days |
| Price at the screen | $4,656.00 |
| Valuation | 1,193.70 trailing · 1,082.38 forward price to earnings |
| Values screen | FAIL · score 10.0 |
Five Screens, Shown in Full
Does not pass. Business activity exclusion: FAIL on business activity
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Excluded | Core business clean | Business activity exclusion: FAIL on business activity | Fail |
| Debt load | Excluded | Below 33% | Interest-bearing debt is of its assets, above the one-third ceiling the screen allows. | Fail |
| Interest-bearing cash | Excluded | Below 33% | Interest-bearing cash and securities are of assets, above the one-third limit. | Fail |
| Receivables | Excluded | Below 49% | Money owed to the company is of assets, above the 49% limit. | Fail |
| Revenue purity | Excluded | Below 5% | of revenue comes from non-compliant sources, over the 5% line. | Fail |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical ReadWhy It Falls Short, in Plain English
British American Tobacco does not clear the screen at the business-activity stage. It operates in an area the screen excludes: Business activity exclusion: FAIL on business activity, so the financial ratios are not the deciding factor here.
Read as at 2026-11-15. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when BATS.L's ethical verdict changes
Today BATS.L does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
The Fair Value Range
Our model only; no analyst estimate to cross-check.
Our analysis reads Overvalued vs our fair value, as of 13 Nov 2026: it trades above our 2,328.00 GBp fair value estimate, 0.10% revenue growth.
How a fair value is estimated: discounted cash flow (DCF).
Fair value range in GBp, drawn from the 2026-11-13 screen. The gold marker is the market price at the same screen. The price runs 100.0% above the base estimate.
Where our models see it going: fair-value estimate 2,328.00 GBp, range not available, dated to the 2026-11-13 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain WordsWhy it gives us pause
At 1,082.4x forward earnings, the price already runs ahead of the business. It trades 100% above our 2,328.00 GBp fair value, so you would be buying at a premium, not a discount.
| Forward P/E | 1,082.4xexpensive even after accounting for its growth |
| Trailing P/E | 1,193.7xexpensive: the price assumes strong growth ahead |
| EPS, trailing | 3.49 |
| EPS, forward | 3.85 |
| Revenue growth | +0.1%slow but positive growth |
| Profit margin | 0.0%currently unprofitable |
| Return on equity | 15.8%a solid return on shareholder capital |
| FCF yield | 3.24% |
| Dividend yield | 5.03% |
| Debt to equity | 0.73moderate, manageable leverage |
| Market cap | $92.3B |
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradeBATS.L trades on LSE. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are up 31%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (11 analysts) rates it buy, with a mean price target of $4950.
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 13% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 31%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (11 analysts) rates it buy, with a mean price target of $4950.
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 7.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 13% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 31%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (11 analysts) rates it buy, with a mean price target of $4950.
The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 13% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 31%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (11 analysts) rates it buy, with a mean price target of $4950.
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 13% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 31%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (11 analysts) rates it buy, with a mean price target of $4950.
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 13% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 31%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (11 analysts) rates it buy, with a mean price target of $4950.
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns.
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-05-18 | Wheaton (Kingsley J) | 781 | $51,952 | ||
| 2026-05-15 | British American Tobacco PLC | 114,426 | $7,443,068 | ||
| 2026-05-14 | British American Tobacco PLC | 112,683 | $7,425,471 | ||
| 2026-05-13 | British American Tobacco PLC | 144,417 | $9,267,960 | ||
| 2026-05-12 | British American Tobacco PLC | 93,605 | $5,732,089 | ||
| 2026-05-11 | British American Tobacco PLC | 127,499 | $7,531,110 | ||
| 2026-05-08 | British American Tobacco PLC | 130,284 | $7,571,194 | ||
| 2026-05-08 | Marroco (Tadeu Luiz) | 371 | $21,676 | ||
| 2026-05-08 | Marroco (Tadeu Luiz) | 6,036 | $364,182 | ||
| 2026-05-07 | Marroco (Tadeu Luiz) | 36 | $2,096 |
Public filings, recorded as found. The full tape lives at Insider Intelligence.
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $4,379.00 | +4.3% | · | $1,043 | +4.3% |
| 2 months | $4,351.00 | +4.9% | · | $1,049 | +4.9% |
| 3 months | $4,367.38 | +4.6% | $61.26 | $1,060 | +6.0% |
| 6 months | $4,382.76 | +4.2% | $121.32 | $1,069 | +6.9% |
| 1 year | $3,497.87 | +30.5% | $241.44 | $1,374 | +37.4% |
| 2 years | $2,398.54 | +90.4% | $478.14 | $2,103 | +110.3% |
| 3 years | $2,584.35 | +76.7% | $710.18 | $2,042 | +104.2% |
| 5 years | $2,795.36 | +63.3% | $1,147.40 | $2,044 | +104.4% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever BATS.L does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.